Molecular imaging in nuclear cardiology: Translating research concepts into clinical applications

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 2, 2010, Pages 230-240

  Sinusas, A J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis inducing agents; Atherosclerosis; Molecular imaging; Ventricular remodeling

Indexed keywords

ACETIC ACID C 11; BRAIN NATRIURETIC PEPTIDE; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; PALMITIC ACID C 11; TRACER;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CYCLOTRON; DRESSLER SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROTRANSMISSION; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC FUNCTION; THROMBOSIS;

CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR REMODELING;

EID: 77958553418     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Higuchi T, Schwaiger M. Non-invasive imaging of heart failure: neuronal dysfunction and risk stratification. Heart Fall Clin 2006;2:193-204.
2. Carrio I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. J Am Coll Cardiol Img 2010;3:92-100.
3. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: Application in the evaluation of cardiac disease. J Nucl Cardiol 2008;15:442.
4. Bashir A, Gropler RJ. Translation of myocardial metabolic imaging concepts into the clinics. Cardiol Clin 2009;27:291-310.
5. Bergmann S, Weinheimer C, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1995;37:1723-30. (Pubitemid 26337187)
6. Brown M, Marshall D, Sobel B, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 1987;76:687-96.
7. Herrero P, Dence C, Coggan A, Kisrieva-Ware Z, Eisenbeis P, Gropler R. L-3-HC-lactate as a PET tracer of myocardial lactate metabolism: a feasibility study. J Nucl Med 2007;48:2046-55.
8. Herrero P, Kisrieva-Ware Z, Dence CS, Patterson B, Coggan AR, Han DH et al. PET measurements of myocardial glucose metabolism with 1-11C-glucose and kinetic modeling. J Nucl Med 2007;48: 955-64.
9. Knapp FJ, Ambrose K, Goodman M. New radio-iodinated methyl-branched fatty acids for cardiac studies. Eur J Nucl Med 1986;12(suppl):s39-44. (Pubitemid 17196706)
10. Shi CQ, Young LH, Daher E, DiBella EV, Liu YH, Heller EN et al. Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. J Nucl Med 2002;43:421-31.
11. Verani MS, Taillefer R, Iskandrian AE, Mahmarian JJ, He ZX, Orlandi C. 123I-IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid. J Nucl Med 2000;41:1299-307.
12. Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE et al. Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005;112:2169-74.
13. Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K et al. Metabolism of Iodine-123-BMIPP in perfused rat hearts. J Nucl Med 1995;36:1043-50.
14. Link JM, Caldwell JH. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med 2008;5(Suppl 2):S79-86.
15. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parízek P, Agostini D et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular anhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
16. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol 2010 [In press].
17. Arimoto T, Takeishi Y, Fukui A, Tachibana H, Nozaki N, Hirono O et al. Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. Ann Nucl Med 2004;18:145-50.
18. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F et al. 1-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121.
19. Sasano T, Abraham MR, Chang KC, Ashikaga H, Mills KJ, Holt DP et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 2008;51:2266.
20. Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 2005;46:1368-74.
21. Fallavollita JA, Banas MD, Suzuki G, deKemp RA, Sajjad M, Canty JM Jr. 11C-meta-hydroxyephedrine defects persist despite functional improvement in hibernating myocardium. J Nucl Cardiol 2010;17:85-96.
22. Sinusas AJ, Bengel F, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging 2008;1:244-56.
23. Nahrendorf M, Sosnovik DE, French BA, Swirski FK, Bengel F, Sadeghi MM et al. Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging 2009;2:56-70.
24. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010;7:38-47.
25. Morrison AR, Sinusas AJ. Advances in radionuclide molecular imaging in myocardial biology. J Nucl Cardiol 2010;17:116-34.
26. Morrison AR, Sinusas AJ. New molecular imaging targets to characterize myocardial biology. Cardiol Clin 2009;27:329-44.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
28. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004;45:1898-907.
29. Iuliano L, Signore A, Vallabajosula S, Colavita AR, Camastra C, Ronga G et al. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man. Atherosclerosis 1996;126:131-41.
30. Lees R, Lees A. Radiopharmaceutical imaging of atherosclerosis. In: Fuster V, editor. Syndromes of atherosclerosis: correlations of clinical imaging and pathology. Armonk, NY: Futura Publishing Co., Inc.; 1996. p. 385-401.
31. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11.
32. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg 2009;37:714-21.
33. Narula J, Petrov A, Bianchi C, Ditlow CC, Lister BC, Dilley J et al. Non-invasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab′)2 specific for the proliferating smooth muscle cells of human atheroma : imaging with conventional and negative charge-modified antibody fragments. Circulation 1995;92:474-84.
34. Carrió I, Pieri PL, Narula J, Prat L, Riva P, Pedrini L et al. Non-invasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol 1998;5:551-7.
35. Moriwaki H, Matsumoto M, Handa N, Isaka Y, Hashikawa K, Oku N et al. Functional and anatomic evaluation of carotid atherothrombosis: a combined study of indium 111 platelet scintigraphy and B-Mode ultrasonography. Arterioscler Thromb Vasc Biol 1995;15:2234-40.
36. Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus imaging with a Technetium-99m-Labeled, activated platelet receptor-binding peptide. J Nucl Med 1996;37:775-81.
37. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS. Imaging Characteristics of a Novel Technetium Tc 99m-Labeled Platelet Glycoprotein IIb/IIIa Receptor Antagonist in Patients With Acute Deep Vein Thrombosis or a History of Deep Vein Thrombosis. Arch Intern Med 2003;163:452-6. (Pubitemid 36241022)
38. Sinusas AJ. Imaging of angiogenesis. J Nucl Cardiol 2004;11: 617-33.
39. Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003;108:97-103.
40. Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 2008;49:667-73.
41. Willmann JK, Chen K, Wang H, Paulmurugan R, Rollins M, Cai W et al. Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 2008;117:915-22.
42. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al. Non-invasive imaging of alpha(v)beta3 integrin expression using 18F- labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
43. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36. (Pubitemid 32150525)
44. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C et al. Design, synthesis, and evaluation of radiolabeled integrin v 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003;18:631-45.
45. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP et al. Non-invasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-91.
46. Kalinowski L, Dobrucki LW, Meoli DF, Dione DP, Sadeghi MM, Madri JA et al. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J Appl Physiol 2008;104:1504-12.
47. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S et al. Non-invasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157-67.
48. Dobrucki LW, Dione DP, Kalinowski L, Dione D, Mendizabal M, Yu J et al. Serial non-invasive targeted imaging of peripheral angiogenesis: validation and application of a semiautomated quantitative approach. J Nucl Med 2009;50:1356-63.
49. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. EurHeart J 2008;29:2201.
50. Sutton M, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circ Res 2000;101: 2981-8. (Pubitemid 30415891)
51. Spinale F. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-30. (Pubitemid 34640901)
52. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
53. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753-8.
54. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003;108:1753-9.
55. Shirani J, Dilsizian V. Imaging left ventricular remodeling: targeting the neurohumoral axis. Nat Clin Pract Cardiovasc Med 2008; 5:S57-S62.
56. Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007;48:182-7. (Pubitemid 47555341)
57. Shirani J, Narula J, Eckelman WC, Narula N, Dilsizian V. Early imaging in heart failure: exploring novel molecular targets. J Nucl Cardiol 2007;14:100-10. (Pubitemid 46172889)
58. Verjans JW, Lovhaug D, Narula N, ov AD, Indrevoll B, Bjurgert E et al. Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging 2008;1:354-62.